In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat

作者：Blondeau J M^*; Borsos S; Blondeau L D; Blondeau B J

来源：Veterinary Microbiology, 2012, 155(2-4): 284-290.

DOI：10.1016/j.vetmic.2011.08.015

• Enrofloxacin
• Killing
• Escherichia coli
• Staphylococcus pseudintermedius
• Pseudomonas aeruginosa

Enrofloxacin is a fluoroquinolone antibacterial agent used to treat infections in companion animals. Enrofloxacin%26apos;s antimicrobial spectrum includes Gram positive and Gram-negative bacteria and demonstrates concentration-dependent bacteriocidal activity. In dogs and cats, enrofloxacin is partially metabolized to ciprofloxacin and both active agents circulate simultaneously in treated animals at ratios of approximately 60-70% enrofloxacin to 30-40% ciprofloxacin. We were interested in determining the killing of companion animal isolates of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin and ciprofloxacin combined using clinically relevant drug concentrations and ratios. For E. coli isolates exposed to 2.1 and 4.1 mu g/ml of enrofloxacin/ciprofloxacin at 50:50, 60:40 and 70:30 ratios, a 1.7-2.5 log(10) reduction (94-99% kill) was seen following 20 min of drug exposure; 0.89-1.7 log(10) (92-99% kill) of S. pseudintermedius following 180 min of drug exposure; 0.85-3.4 log(10) (98-99% kill) of P. aeruginosa following 15 min of drug exposure. Killing of S. pseudintermedius was enhanced in the presence of enrofloxacin whereas killing of P. aeruginosa was enhanced in the presence of ciprofloxacin. Antagonism was not seen when enrofloxacin and ciprofloxacin were used in kill assays. The unique feature of partial metabolism of enrofloxacin to ciprofloxacin expands the spectrum of enhanced killing of common companion animal pathogens.

• 出版日期2012-3-23